文献速递肿瘤 PET/CT

68Ga-FAPI-04 PET/CT对胃癌分期与预后的贡献

The Contribution of 68 Ga-FAPI-04 PET/CT to Staging and Prognosis in Gastric Cancer.
PubMed 文献 · Clin Nucl Med · 2024-07-31

本研究纳入31例胃癌分期患者,比较18F-FDG PET/CT与68Ga-FAPI-04 PET/CT的诊断能力。68Ga-FAPI-04对原发肿瘤检出率更高(96.7% vs 77.4%,P=0.006和P=0.008),阳性淋巴结检出更多(P=0.026),腹膜受累SUVmax和靶本比更高(均P=0.04),两种显像剂对器官转移和疾病分期的检出无显著差异(P>0.05)。

要点

  • 68Ga-FAPI-04对原发肿瘤检出率96.7%,高于18F-FDG的77.4%。
  • 68Ga-FAPI-04阳性淋巴结检出显著更多(P=0.026)。
  • 腹膜受累SUVmax和靶本比68Ga-FAPI-04更高(均P=0.04)。

核心结论

  • 68Ga-FAPI-04 PET/CT在检出原发肿瘤方面优于18F-FDG PET/CT,尤其在低黏附性、印戒细胞和黏液亚型中。
  • 68Ga-FAPI-04 PET/CT在疾病分期方面提供更高准确性,提示其可能改善胃癌患者的治疗管理和预后评估。

研究设计与样本

  • 本研究纳入31例接受胃癌分期检查的患者,均接受18F-FDG PET/CT和68Ga-FAPI-04 PET/CT扫描。
  • 研究比较两种显像的原发肿瘤和淋巴结SUVmax、SUVmean、器官转移计数、靶本比及总体分期准确性,并评估放射学无进展生存期和总生存率。

主要发现

  • 68Ga-FAPI-04 PET/CT对原发肿瘤的检出率为96.7%,18F-FDG PET/CT为77.4%(P=0.006和P=0.008)。
  • 68Ga-FAPI-04 PET/CT检出阳性淋巴结显著更多(P=0.026),但基于患者的SUVmax和靶本比无显著差异(P>0.05)。
  • 腹膜受累的SUVmax和靶本比在68Ga-FAPI-04 PET/CT上均显著高于18F-FDG PET/CT(均P=0.04)。
  • 两种显像方法对器官转移和疾病分期的检出无显著差异(P>0.05)。
  • 两种显像的原发肿瘤摄取对放射学无进展生存期或总生存率均无显著影响。

临床怎么用

  • 原文结论指出68Ga-FAPI-04 PET/CT在检出原发肿瘤(尤其低黏附性和印戒细胞胃癌)及疾病分期准确性方面优于18F-FDG PET/CT,提示其可能改善胃癌患者的治疗管理和预后评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: This study aimed to compare the diagnostic capabilities of 18 F-FDG PET/CT and 68 Ga-FAPI-04 PET/CT imaging in staging gastric carcinoma, exploring the impact of 68 Ga-FAPI-04 PET/CT on treatment planning and its prognostic significance. METHODS: The research included 31 patients undergoing staging for gastric cancer, who received both 18 F-FDG PET/CT and 68 Ga-FAPI-04 PET/CT scans. We compared the SUV max and SUV mean of the primary tumor and lymph nodes, the count of organ metastases, tumor-to-background ratios, and overall staging accuracy. Additionally, the study evaluated radiological progression-free survival and overall survival rates. RESULTS: The 68 Ga-FAPI-04 PET/CT demonstrated superior efficacy in identifying the primary tumor compared with 18 F-FDG PET/CT, particularly in cases of poorly cohesive, signet-ring cell, and mucinous subtypes, with detection rates of 96.7% versus 77.4% ( P = 0.006 and P = 0.008, respectively). Analysis of lymph nodes showed a significantly higher detection of positive nodes with 68 Ga-FAPI-04 ( P = 0.026), although no significant differences were observed in SUV max and tumor-to-background ratio on a patient basis ( P > 0.05). SUV max and tumor-to-background ratios for peritoneal involvement were notably higher with 68 Ga-FAPI-04 PET/CT compared with 18 F-FDG PET/CT ( P = 0.04 for both). No significant differences were found in the detection of organ metastases and disease stage between the 2 imaging modalities ( P > 0.05). Primary tumor uptake did not significantly impact radiological progression-free survival or overall survival in either modality. CONCLUSIONS: 68 Ga-FAPI-04 PET/CT imaging surpasses 18 F-FDG PET/CT in detecting the primary tumor, especially in poorly cohesive and signet-ring cell gastric cancer types, and offers improved accuracy in disease staging. This indicates its potential to enhance treatment management and prognostic assessment in gastric cancer patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Beyhan E, Çermik TF, Erol Fenercioğlu Ö, et al. The Contribution of 68 Ga-FAPI-04 PET/CT to Staging and Prognosis in Gastric Cancer. Clin Nucl Med. 2024. PMID: 39086038. doi:10.1097/RLU.0000000000005394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。